Compass Pathways (CMPS) to Release Earnings on Thursday

Compass Pathways (NASDAQ:CMPS) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:00 AM ET.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.59). On average, analysts expect Compass Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Compass Pathways Price Performance

NASDAQ CMPS traded down $0.21 on Tuesday, hitting $9.32. The stock had a trading volume of 2,203,501 shares, compared to its average volume of 3,538,179. The firm has a 50-day moving average of $6.77 and a 200-day moving average of $6.53. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -3.01 and a beta of 2.39. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.77 and a current ratio of 0.77. Compass Pathways has a 52-week low of $2.25 and a 52-week high of $10.21.

Hedge Funds Weigh In On Compass Pathways

Hedge funds and other institutional investors have recently modified their holdings of the company. Persistent Asset Partners Ltd purchased a new stake in shares of Compass Pathways during the fourth quarter worth about $38,000. Advisory Services Network LLC purchased a new stake in Compass Pathways in the 3rd quarter worth approximately $41,000. MML Investors Services LLC bought a new stake in shares of Compass Pathways in the 4th quarter worth approximately $69,000. Magnetar Financial LLC bought a new stake in shares of Compass Pathways in the 4th quarter worth approximately $91,000. Finally, Raymond James Financial Inc. increased its stake in shares of Compass Pathways by 82.7% during the third quarter. Raymond James Financial Inc. now owns 13,763 shares of the company’s stock valued at $79,000 after buying an additional 6,228 shares during the period. 46.19% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CMPS. UBS Group set a $17.00 price objective on Compass Pathways in a research note on Friday, April 24th. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. B. Riley Financial started coverage on Compass Pathways in a research note on Friday, April 24th. They issued a “buy” rating and a $17.00 target price on the stock. Canaccord Genuity Group lowered their price target on Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, March 26th. Finally, Royal Bank Of Canada lifted their target price on shares of Compass Pathways from $21.00 to $22.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Compass Pathways presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.45.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.